Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note published on Tuesday morning,Benzinga reports. They currently have a $7.00 price objective on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, January 22nd.

Anixa Biosciences Trading Down 3.8 %

Anixa Biosciences stock opened at $3.02 on Tuesday. The stock has a market cap of $97.24 million, a P/E ratio of -7.74 and a beta of 0.93. The company has a fifty day simple moving average of $2.70 and a 200-day simple moving average of $3.05. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. As a group, sell-side analysts forecast that Anixa Biosciences will post -0.46 earnings per share for the current fiscal year.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of Anixa Biosciences stock in a transaction on Friday, January 17th. The shares were bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 75,289 shares of company stock worth $177,021 over the last ninety days. 22.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. International Assets Investment Management LLC increased its position in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Tyler Stone Wealth Management increased its position in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the last quarter. Virtu Financial LLC acquired a new position in Anixa Biosciences during the third quarter worth approximately $34,000. Westside Investment Management Inc. increased its position in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Finally, Prosperity Wealth Management Inc. acquired a new position in Anixa Biosciences during the fourth quarter worth approximately $54,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.